Chengda Pharmaceutical Co., Ltd
Initial public offering and listing on the gem
Suggestive announcement of listing announcement
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
With the approval of Shenzhen Stock Exchange, the RMB common shares issued by Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as “the issuer” or “the company”) will be listed on the gem of Shenzhen Stock Exchange on January 20, 2022, The full text of the listing announcement and the full text of the prospectus for the initial public offering of shares are disclosed on the websites designated by the CSRC (http://www.cn.info.com.cn; www.cs.com.cn; www.cn.stock.com; www.stcn.com; www.zqrb.cn), QR code of the web page: http://www.cninfo.com.cn for investors.
1、 Listing overview
(I) stock abbreviation: Chengda pharmaceutical
(II) Stock Code: 301201
(III) total share capital after IPO: 96.696140 million shares
(IV) number of initial public offering shares: 24174035 shares. This issuance is all new shares without transfer of old shares. 2、 Risk tips
The company’s shares will be listed on the growth enterprise market of Shenzhen Stock Exchange, which has high investment risk. GEM companies have the characteristics of unstable performance, high operation risk and high delisting risk, and investors are facing greater market risk. Investors should fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
The issue price is 72.69 yuan / share. According to the guidelines for Industry Classification of listed companies (revised in 2012) (CSRC announcement [2012] No. 31), the industry of the company is “pharmaceutical manufacturing industry (C27)”. As of January 4, 2022 (T-4), the static average p / E ratio of C27 pharmaceutical manufacturing industry released by China Securities Index Co., Ltd. in the latest month is 38.90 times.
As of January 4, 2022 (T-4), the valuation level of comparable listed companies with main business and business model similar to that of the issuer is as follows:
T-4 day stock 2020 deduction 2020 deduction corresponding static corresponding static securities code securities abbreviation closing price non front EPS non back EPS P / E ratio (Times) (yuan / share) (yuan / share) (yuan / share) – deduction non front – deduction non back
603259.SH Wuxi Apptec Co.Ltd(603259) 108.80 1.0015 0.8070 108.64 134.82
002821.SZ Asymchem Laboratories (Tianjin) Co.Ltd(002821) 391.50 2.7448 2.4478 142.63 159.94
300363.SZ Porton Pharma Solutions Ltd(300363) 76.62 0.5959 0.5294 128.58 144.73
603456.SH Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) 51.05 0.4571 0.3871 111.68 131.88
688076.SH Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) 40.50 0.5790 0.4432 69.95 91.38
Average 112.30 132.55
Data source: wind information, data as of January 4, 2022 (T-4)
Note 1: if there is mantissa difference in the calculation of P / E ratio, it is caused by rounding;
Note 2: EPS before / after deduction of non recurring profit and loss in 2020 = net profit attributable to the parent before / after deduction of non recurring profit and loss in 2020 / total share capital on T-4 day. The issuance price of 72.69 yuan / share corresponds to the lower of the issuer’s net profit attributable to the shareholders of the parent company before and after deducting non recurring profits and losses in 2020. The diluted P / E ratio is 83.10 times, which is 38.90 times higher than the industry’s static average p / E ratio in the latest month published by China Securities Index Co., Ltd. and 132.55 times lower than that of comparable listed companies after deducting non recurring profits and losses in 2020, However, there is still a risk that the decline of the issuer’s share price will bring losses to investors in the future. There is a risk that the net asset scale will increase significantly due to the acquisition of raised funds, which will have an important impact on the issuer’s production and operation mode, operation management and risk control ability, financial status, profitability and long-term interests of shareholders. The issuer and the recommendation institution (lead underwriter) remind investors to pay attention to investment risks, carefully study and judge the rationality of issuance pricing, and make investment decisions rationally.
The company reminds investors to pay attention to the investment risks at the initial stage of IPO listing. Investors should fully understand the risks and rationally participate in the trading of new shares.
3、 Contact information (I) contact address and telephone number of the issuer
Issuer: Chengda Pharmaceutical Co., Ltd
Contact address: No. 36, Huanghe Road, Huimin street, Jiashan County, Jiaxing City, Zhejiang Province
Contact: Yang Xiaojing
Tel.: 0573-84601188 (Ⅱ) contact address and Tel. of the sponsor
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
Contact address: No. 1508, Xinzha Road, Jing’an District, Shanghai
Sponsor representatives: Yang Ke, fan Guozu
Tel.: 021-22169999
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Chengda Pharmaceutical Co., Ltd. on its initial public offering and listing on the GEM)
Chengda Pharmaceutical Co., Ltd
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Chengda Pharmaceutical Co., Ltd. on its initial public offering and listing on the GEM)
Everbright Securities Company Limited(601788) mm / DD / yy
